Triple-action treatment for improved outcomes for slow-healing leg ulcers, pressure sores and diabetic ulcers

在英国，每年约有100万名患者因复杂的、愈合缓慢的腿部溃疡、糖尿病溃疡或压疮而接受治疗。他们需要在家里或在当地诊所更换伤口敷料，有时一周一次，有时每天。该项目的目标是开发一种敷料形式的伤口治疗方法，以解决护理这些复杂的不可愈合伤口方面的主要挑战，改善患者的生活，并节省NHS每年用于伤口护理的估计50亿英镑的一部分。随着英国人口老龄化、肥胖症的增加和2型糖尿病的流行，越来越多的人需要在家中或在初级保健中治疗愈合缓慢的腿部溃疡、压疮和糖尿病足部溃疡。该项目将多种治愈伤口的好处结合在一起，在一种敷料中治愈伤口，穿戴时间长，可以在社区环境中使用。伤口通常处于慢性炎症状态，很可能会有细菌生物膜，减缓或阻止愈合过程。到目前为止，我们进行的研究表明，我们可以在一种敷料中结合使用一种抗炎化合物，这种化合物可以加速伤口愈合，并能够减少伤口的复发感染，并从伤口吸收大量液体。这有望成为满足上述社会需求的突破性解决方案。IO-Cyte Ltd([www.io-cyte.co.uk][0])是一家新的创伤护理技术公司，它是从西罗斯有限公司剥离出来的，西罗斯有限公司是一家老牌的专门从事矫形外科的公司。这项工作来自于西罗斯生物材料研究机构的研究。Io-Cyte将开发并推向市场的产品是基于我们已经申请的专利。[0]：http://www.io-cyte.co.uk/

Around one million patients in the UK are treated every year for complex, slow-healing leg ulcers, diabetic ulcers or pressure sores. They need their wound dressings changed at home or at their local practice, sometimes once a week and sometimes every day. The goal of the project is to develop a wound treatment in dressing form that addresses the major challenges in caring for these complex non-healing wounds, improving the lives of patients and saving some of the estimated £5bn per year that the NHS spends on wound care. With the UK's aging population, the rise in obesity and the epidemic of Type 2 diabetes there is increasing need to treat slow-healing leg ulcers, pressure sores and diabetic foot ulcers at home or in primary care.This project combines multiple benefits for healing wounds in one treatment in a dressing with a long wear time that can be used in community setting. Wounds are often "stuck" in a chronically inflamed state and are likely to have bacterial biofilms that slow down or stop the healing process. Our research carried out to date shows we can combine in a single dressing an anti-inflammatory compound that can speed up wound healing with an ability to reduce the recurring infections in wounds and absorb large amounts of fluid from the wound. This promises to be a break-through solution for the societal needs identified above.Io-Cyte Ltd ([www.io-cyte.co.uk][0]) is a new woundcare technology company that has been spun-out from Xiros Ltd, an established company specialising in orthopaedics. The work comes from research done in Xiros' biomaterials research facility. The product that Io-Cyte will develop and bring to the market is based on the patents that we have filed.[0]: http://www.io-cyte.co.uk/